Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
Authors:
- 8 December 2013
- journal article
- Published by Springer Nature in Tumor Biology
- Vol. 35 (4) , 2941-2948
Abstract
Polymorphisms in the excision repair cross-complimentary group 1 (ERCC1)–excision repair cross-complimentary group 4 (ERCC4) genes have been implicated in the prognosis of various cancers. We conducted a cohort study to investigate the role of ERCC1–ERCC4 gene polymorphisms on the response to chemotherapy and the role of these two gene polymorphisms on the clinical outcomes of gastric cancer. Four hundred forty-seven patients with newly diagnosed and histopathologically confirmed primary gastric cancer were collected in our study and were followed up until March 2012. ERCC1 (rs11615, rs3212986C>A, and rs2298881) and ERCC4 (rs226466C>G, rs2276465, and rs6498486) were selected and genotyped. The overall chemotherapy response rate for treatment was 68 %. Carriers of the rs11615 TT and T allele and ERCC1 rs2298881 CC and C allele had a marginally significantly higher response rate to the chemotherapy. In the Cox proportional hazard model, the hazard ratios (HRs) for overall survival (OS) in patients carrying ERCC1 rs11615 TT genotype and T allele were 0.53 (0.29–0.95) and 0.63 (0.42–0.94), respectively. Similarly, we found a significant decreased risk of death from gastric cancer among patients carrying ERCC1 rs2298881 CC genotype and C allele when compared with CC genotype, and HRs (95 % confidence interval (CI)) of OS were 0.50 (0.24–0.98) and 0.62 (0.40–0.96), respectively. Moreover, individuals carrying ERCC1 rs11615 T allele and rs2298881 C allele could decrease a 0.62-fold risk of death from gastric cancer. This study reported a carriage of ERCC1 rs11615, and rs2298881 polymorphism can be used as a predictor of response to folinic acid/5-fluorouracil (5-FU)/oxaliplatin (FOLFOX)-based chemotherapy in gastric cancer patients.Keywords
This publication has 49 references indexed in Scilit:
- Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: A pooled analysis based on 39 reportsGene, 2013
- Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapyCancer Chemotherapy and Pharmacology, 2013
- ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatinBritish Journal of Cancer, 2013
- Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic reviewBMC Gastroenterology, 2012
- XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and NeckClinical Cancer Research, 2011
- DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast CancerClinical Cancer Research, 2010
- ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxelBMC Cancer, 2008
- Polymorphisms in DNA repair genes and associations with cancer risk.2002
- Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapyCancer Treatment Reviews, 1998
- Reaction Mechanism of Human DNA Repair Excision NucleaseJournal of Biological Chemistry, 1996